AngioDynamics, Inc. (NASDAQ:ANGO) Stake Reduced by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC reduced its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 46.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 135,350 shares of the medical instruments supplier’s stock after selling 119,184 shares during the quarter. Cubist Systematic Strategies LLC owned about 0.33% of AngioDynamics worth $1,240,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Balyasny Asset Management L.P. grew its stake in AngioDynamics by 77.8% during the 4th quarter. Balyasny Asset Management L.P. now owns 110,851 shares of the medical instruments supplier’s stock worth $1,015,000 after buying an additional 48,522 shares during the last quarter. Ameriprise Financial Inc. grew its stake in AngioDynamics by 24.0% during the 4th quarter. Ameriprise Financial Inc. now owns 277,565 shares of the medical instruments supplier’s stock worth $2,542,000 after buying an additional 53,675 shares during the last quarter. Manatuck Hill Partners LLC grew its stake in shares of AngioDynamics by 166.0% in the fourth quarter. Manatuck Hill Partners LLC now owns 199,500 shares of the medical instruments supplier’s stock worth $1,827,000 after purchasing an additional 124,500 shares in the last quarter. Northern Trust Corp grew its stake in shares of AngioDynamics by 2.4% in the fourth quarter. Northern Trust Corp now owns 351,365 shares of the medical instruments supplier’s stock worth $3,219,000 after purchasing an additional 8,260 shares in the last quarter. Finally, Nebula Research & Development LLC bought a new position in shares of AngioDynamics in the fourth quarter worth $125,000. 89.43% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $16.00 price target (up previously from $15.00) on shares of AngioDynamics in a research note on Monday, April 7th.

AngioDynamics Stock Down 1.8%

Shares of AngioDynamics stock opened at $9.40 on Wednesday. The firm has a market cap of $381.71 million, a price-to-earnings ratio of -1.67 and a beta of 0.58. The business has a fifty day simple moving average of $9.42 and a 200-day simple moving average of $9.35. AngioDynamics, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $13.50.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Wednesday, April 2nd. The medical instruments supplier reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.16. The business had revenue of $72.00 million during the quarter, compared to analyst estimates of $70.30 million. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The business’s revenue for the quarter was down 4.3% on a year-over-year basis. Analysts anticipate that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.